Singular Genomics Systems, Inc. Stock price

Equities

OMIC

US82933R1005

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.5142 USD -0.50% Intraday chart for Singular Genomics Systems, Inc. +4.36% +11.76%
Sales 2024 * 3.65M Sales 2025 * 18.93M Capitalization 38.01M
Net income 2024 * -87M Net income 2025 * -82M EV / Sales 2024 * 4.08 x
Net cash position 2024 * 23.1M Net Debt 2025 * 23.43M EV / Sales 2025 * 3.25 x
P/E ratio 2024 *
-0.42 x
P/E ratio 2025 *
-0.47 x
Employees 255
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.87%
More Fundamentals * Assessed data
Dynamic Chart
UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating MT
Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q4 Revenue $1.1M, vs. Street Est of $1.04M MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Singular Genomics Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Investors -2- DJ
Transcript : Singular Genomics Systems, Inc. - Special Call
Singular Genomics Systems, Inc. Showcases New G4X? Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4 Sequencing Platform CI
Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis CI
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating MT
Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023 CI
Singular Genomics Systems Expects 31% Growth in Q4 Revenue MT
Transcript : Singular Genomics Systems, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q3 Revenue $0.5M MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news

Latest transcript on Singular Genomics Systems, Inc.

1 day-0.50%
1 week+4.36%
Current month-9.79%
1 month-12.37%
3 months+9.17%
6 months+35.32%
Current year+11.76%
More quotes
1 week
0.48
Extreme 0.4774
0.53
1 month
0.48
Extreme 0.4774
0.62
Current year
0.40
Extreme 0.4
0.66
1 year
0.31
Extreme 0.3101
1.32
3 years
0.31
Extreme 0.3101
33.37
5 years
0.31
Extreme 0.3101
33.37
10 years
0.31
Extreme 0.3101
33.37
More quotes
Managers TitleAgeSince
Founder 55 16-05-31
Chief Executive Officer 39 16-05-31
Director of Finance/CFO 46 19-11-30
Members of the board TitleAgeSince
Founder 82 16-08-31
Director/Board Member 56 17-04-30
Director/Board Member 58 17-03-31
More insiders
Date Price Change Volume
24-03-28 0.5142 -0.50% 57,356
24-03-27 0.5168 +1.12% 110,408
24-03-26 0.5111 +1.21% 72,998
24-03-25 0.505 -1.94% 87,377
24-03-22 0.515 +4.53% 70,222

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.5142 USD
Average target price
0.675 USD
Spread / Average Target
+31.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Singular Genomics Systems, Inc. - Nasdaq